Key Words
Instructions for Formatting Abstracts
• Submission deadline: November 01, 2025
• Date of publication of approved papers: December 01, 2025
• All approved abstracts will be published in the Journal of Medical Imaging and Radiation Sciences.
• Abstracts must be submitted exclusively via the form online Abstract Submission Services only.
• To submit an abstract, the presenting author must be registered in the event
THE PAPER TOPICS MUST BE RELATED TO
o Alpha Therapy – Clinical applications
o Alpha Therapy – Preclinical studies
o Alpha emitters – Production and supply
o Alpha emitters – Radiochemistry & Radiopharmacy
o Alpha emitters – Medical Physics
o Alpha emitters – Quality control & regulation
o Beta Therapy – Clinical applications
o Beta Therapy – Pre-clinical studies
o Beta emitters – Radiochemistry & Radiopharmacy
o Beta emitters – Medical Physics
o Beta emitters – Quality control & regulation
TYPES OF ACCEPTED PAPERS
o Basic research
o Clinical research
o Preclinical research
o Case reports
o Meta-analyses
o Systematic reviews o Reviews
GENERAL STRUCTURE
The character limit is set automatically by the system and includes "spaces", special characters and titles.
The use of graphs, images, tables and references will not be permitted.
REQUIRED TOPICS (maximum 3,500 characters with title)
• Title
• Authors and Affiliations
• Introduction/Justification
• Objectives
• Materials and Methods
• Results
• Conclusion
• Key Words
• Funding acknowledgements
Title - The grading and selection process is blinded. Please do not include authors, institutions, city names and trademarks in the title.
Authors and Affiliations - The first author should be the abstract presenter by default. Nevertheless, it can be modified via agreement form available upon request by email ([email protected]) until March 10, 2026. The authors’ names and affiliations will be published as listed on the submission form. The submitter certifies that he/she has permission from all authors to be listed in the conference abstract and that they are aware that their names will appear in all publications. If none of the authors can present the abstract during the conference, the abstract should be withdrawn.
Abstract content - Abstracts should be submitted in English. Abstracts must contain original material not published elsewhere prior to the TAT13 (in print or electronically).
• Text must not contain identifying features, i.e. information such as authors’ names and surnames, names of the institution (hospitals, universities, clinics, etc) and cities. These identifying features should be replaced in the text with the word “BLINDING” in capital letters.
• Text must not contain trademarks (instead, use generic devices/drug names), company names, location, websites and email addresses.
Failure to comply with the above requirements will lead to automatic rejection of the submission.
Studies involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki, according to the national law – if applicable, and approved by an appropriate ethics committee. Authors are encouraged to provide institutional review board (IRB) approval number (e.g. ethics committee) and/or indexed platform registration number (e.g. http://clinicaltrials.gov or http://www.ensaiosclinicos.gov.br).
Abstract submitted on animal studies must follow the "Guide for the Care and Use of Experimental Animals” published by the National Institutes of Health (NIH, revised in 2011, 8th edition), in agreement to the national law – if applicable, and approved by an appropriate ethics committee. Authors are encouraged to provide institutional review board (IRB) approval number (e.g. ethics committee) and/or the indexed platform registration number.
Keywords - Authors must Include 3 keywords. It is recommended to use terms from the Medical Subject Headings (MESH; http://www.nlm.nih.gov/mesh/) or Health Sciences Descriptors (DeCS; http://decs.bvs.br/).
Funding Acknowledgements - All sources of financial support (including governmental grants) related to the abstract should be listed under the appropriate heading. All grant funding agency abbreviations should be spelled out. This information will be published. Do not include grant acknowledgements in the abstract content. Use the appropriate field at the online submission platform.
Table and figures – Should NOT to be included in the abstract.
References - Should NOT to be included in the abstract.
SUBMISSION INFORMATION
Abstract preview and submission - Click on the SAVE AND SUBMIT ABSTRACT button to validate your abstract submission. After having submitted your abstract, you will receive an immediate automatic confirmation by email notifying the abstract number. Please use this number in all future correspondences. If you do not receive this confirmation, please contact the organizing committee by email [email protected].
• The same research cannot be submitted twice, even under a different category or with a different title. If you submit more than one abstract with the same content, the abstract submission service will automatically keep the most recent abstract submitted and withdraw the others.
• If you have difficulties in submitting your abstracts or if you need any further information, please contact the organizing committee ([email protected]).
• Abstracts are only suitable for revision after being submitted. Otherwise, it will be saved in Draft Status when you will be able to review and submit the abstract later. Abstracts that are in draft status after the deadline cannot be processed and therefore will not be considered for revision.
Changes and corrections - Once submitted, it is not possible to make any amendments to the abstract content or authors/affiliation details. To correct your abstract, you must withdraw it and submit a new corrected version prior to the deadline. In the case of mistakes/errors in your abstract noticed after the deadline, you may indicate the correction during the presentation at the conference. However, changes will not be included in the archives of the conference and your abstract will be published as initially submitted.
Withdrawal - If you wish to withdraw an abstract already submitted, please notify [email protected] stating the title and number of the abstract to be withdrawn by March 10, 2026.
ABSTRACT GRADING/RESULTS
• Each reviewer is selected by the Scientific Committee to review abstracts in their category that best fits their expertise.
• All reviewers are blinded regarding the origin of the abstract.
• Submissions are peer-reviewed for scientific content, logical presentation, and current interest of the topic to the scientific community.
• The final selection will be made by the TAT13 Abstract Selection Committee that will determine the format, day and time of presentation for each abstract. No rescheduling or abstract changes will be possible.
• All accepted abstracts will be presented either as Oral Presentations or E-Poster Presentations, based on their grade.
PRESENTATION TYPES
Oral sessions - Presenters will have to summarise their research in a seven-minute presentation and interact with the audience afterwards for 2 minutes. Discussions will be led by experts chairing the session.
E-poster sessions - Consists of visual electronic display of the research, which can be visited by other researchers. In this type of session, the posters will be presented in a poster format to appointed moderators in front of an audience. The audience is welcome to join in the discussion.
English
Português